↓ Skip to main content

A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies

Overview of attention for article published in Investigational New Drugs, June 2006
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (71st percentile)

Mentioned by

patent
7 patents

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
4 Mendeley
Title
A Phase I study of the oral antimetabolite, CS-682, administered once daily 5 days per week in patients with refractory solid tumor malignancies
Published in
Investigational New Drugs, June 2006
DOI 10.1007/s10637-006-8219-0
Pubmed ID
Authors

Jill Gilbert, Michael A. Carducci, Sharyn D. Baker, Elizabeth C. Dees, Ross Donehower

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 4 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 4 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 1 25%
Researcher 1 25%
Other 1 25%
Unknown 1 25%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 1 25%
Agricultural and Biological Sciences 1 25%
Medicine and Dentistry 1 25%
Unknown 1 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 29 April 2021.
All research outputs
#4,767,543
of 23,065,445 outputs
Outputs from Investigational New Drugs
#166
of 1,175 outputs
Outputs of similar age
#11,902
of 64,411 outputs
Outputs of similar age from Investigational New Drugs
#2
of 4 outputs
Altmetric has tracked 23,065,445 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,175 research outputs from this source. They receive a mean Attention Score of 4.7. This one has done well, scoring higher than 79% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 64,411 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 71% of its contemporaries.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.